A Phase I Trial Using Cyclophosphamide, Rituximab and Revlimid (CR2) for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL) and SLL

Status
Active
Cancer Type
Leukemia
Trial Phase
Phase I
Eligibility
18 and over, Male and Female
Study Type
Treatment
NCD ID
NCT01005979
Protocol IDs
WCI1642-09 (primary)
Study Sponsor
Winship Cancer Institute of Emory University

Summary

The purpose of this study is to determine the maximum tolerated dose (MTD), safety and toxicity when cyclophosphamide, rituximab and lenalidomide (Revlimid) are combined for the treatment of relapsed/refractory of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).